Suppliers / Huzhou Zhanwang Pharmaceutical

Huzhou Zhanwang Pharmaceutical

China 1 employees Updated 9 July 2026

Huzhou Zhanwang Pharmaceutical is an API manufacturer based in China. It holds 2 active US drug master files across a filed portfolio of 5 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 29 March 2024 as NAI.

2
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 29 March 2024 NAI US FDA
  • 8 April 2016 NAI US FDA
  • 13 September 2013 VAI US FDA
  • 16 September 2010 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 1000613242

What they file, and where

Molecule Regulators Docs
Methotrexate SFDA (Saudi Arabia), US FDA 3
Leucovorin Calcium SFDA (Saudi Arabia), US FDA 2
Esmolol SFDA (Saudi Arabia) 1
Milrinone SFDA (Saudi Arabia) 1
Pemetrexed Disodium Hemipentahydrate SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Esmolol API Leucovorin API Methotrexate API Milrinone API Pemetrexed Disodium Hemipentahydrate API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Huzhou Zhanwang Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 29 March 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates